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Recent studies indicate that metabolic disorders such as diabetes and obesity are a major risk 
factor of psychiatric diseases. This relationship opens the opportunity to develop new 
antidepressant drugs by repurposing antidiabetic drugs. Previous research has demonstrated 
that GLP-1 analogs are neuroprotective in several neurological disease models including 
Alzheimer’s disease (AD), Parkinson’s disease (PD), and stroke. In addition, the GLP-1 
analog liraglutide has been shown to promote neurogenesis, which is seen to play important 
roles in memory formation and cognitive and emotional processing. However, whether 
liraglutide is an effective antidepressant remains unknown. Therefore, we tested this 
hypothesis in the depression model of chronic administration of corticosterone (CORT) in 
mice and treated the animals daily with liraglutide (5 or 20nmol/kg ip.) to assess its 
therapeutic potential as an antidepressant. Behavioral studies showed that liraglutide 
administration attenuated depressive- and anxiety- like behaviors in this depression mouse 
model, and attenuated the hyperactivity induced by the stress hormone. Additionally, 
liraglutide treatment protected synaptic plasticity and reversed the suppression of 
hippocampal long-term potentiation induced by CORT administration, demonstrating 
synaptic protective effects of liraglutide. We also found that liraglutide treatment increased 
the cell density of immature neurons in the subgranular dentate gyrus region of the 
hippocampus. In addition, liraglutide prevented the CORT induced impairments and 
simultaneously increased the level of phosphorylated GSK3β in the hippocampus, which may 
be instrumental in the anti-depressant activity of liraglutide treatment. Taken together, 
liraglutide has the potential to act as a therapeutic treatment of depression.  
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Depression is one of the major causes of disability and a main health burden in the world. 
Emotional behaviors are influenced and controlled by the activity of the hippocampus, which 
is a brain region that shows high synaptic plasticity to enable animals to adapt to 
environmental challenges (LeDoux, 1993). Therefore, maintaining normal hippocampal 
neural function is one of the main targets in the therapeutic treatment of depression. Synaptic 
plasticity in the hippocampus plays critical roles in emotional memory and learning 
processes, which may be encoded in long-term potentiation (LTP) of synaptic plasticity in the 
hippocampus (Hölscher, 2003; LeDoux, 1993). Adult neurogenesis, the continuous process of 
neural stem cells (NCSs) dividing and developing into mature neurons in the adult brain, has 
been suggested to play a role in depression (Santarelli et al., 2003). In addition, most 
traditional antidepressant drugs promote neurogenesis in the adult hippocampus (Surget et al., 
2008). Stress hormones such as corticosterone (CORT) can induce depression, and chronic 
CORT injection is an animal model of inducing a form of depression (Jalewa et al., 2014). 
CORT treatment also impairs hippocampal long-term potentiation (LTP), a cellular model of 
memory formation. This is an important pathophysiological feature in depression (Pavlides et 
al., 1993). There are several molecular pathways that play a role in promoting hippocampal 
neurogenesis and LTP. In depression, stress induced hyperactivity of the hypothalamus-
pituitary-adrenal (HAP) axis induces persistently elevated levels of glucocorticoids and 
stimulate hippocampal glucocorticoid receptors (GR), which subsequently results in the 
suppressed proliferation of adult NSCs (Egeland et al., 2015). In addition, previous studies 
show that high corticosterone levels cause a suppression in LTP in the hippocampus (Pavlides 
et al., 1996). Furthermore, enhanced GSK3β activity has been observed in depression, and 
appears to play a role in the impairment of neural precursor proliferation by the GR agonist 
dexamethasone (Boku et al., 2009). The increase of GSK3β activity was also found to reduce 
LTP (Peineau et al., 2007). Moreover, inhibiting GSK3β activity was found to improve 
hippocampus-dependent learning and rescued impaired adult hippocampal neurogenesis in a 
mouse model of fragile X syndrome (Guo et al., 2012). In animal models of depression, 
reducing GSK3β activity with lithium improved stress-induced changes in depression-like 
behavior (Silva et al., 2008). 
Previous studies indicate that metabolic disorders like obesity and diabetes are one of the 
major risk factors of psychiatric disorders including depression (Auxier et al., 2012; Khater 
and Omar, 2017). Indeed, the successful use of antidiabetic agents in neurological diseases 
gave rise to the idea that the same drugs may have beneficial effects on depression. GLP-1 is 
an incretin hormone and plays a role in the regulation of blood glucose levels and insulin 
sensitivity (Kahn et al., 2006). GLP-1 analogs like liraglutide have been in use as antidiabetic 
agents for many years (Tran et al., 2017). Several studies that clearly show beneficial actions 
in mouse models of diabetes-obesity (Porter et al., 2013). In addition, previous studies 
demonstrated that liraglutide has neuroprotective effects in neurological disease models such 
as Alzheimer’s disease (AD), Parkinson’s disease (PD) as well as stroke (Han et al., 2013a; 
Liu et al., 2015; McClean and Holscher, 2014; Sato et al., 2013). However, whether 
liraglutide has antidepressive effects in the chronic elevated (Hypothalamus-Pituitary-
Adrenal) HPA axis -induced depression model and whether liraglutide can improve the 
impairment of hippocampal neural plasticity associated with depression has not been reported 
previously. The enhancing effects of liraglutide on hippocampal plasticity in wild type rats or 
transgenic mouse model of Alzheimer’s disease has been shown before (Han et al., 2013b; 
McClean et al., 2010; McClean and Holscher, 2014). To further investigate the effects of 
liraglutide on CORT induced synaptic impairment, we performed LTP recording in the 
hippocampal area CA1. Additionally, it is not known if liraglutide can regulate GSK3β 
activity or the beta-catenin pathway in an animal model of depression. Therefore, we used the 
chronic administration of corticosterone (CORT) depression mouse model (Jalewa et al., 
2014) to test this hypothesis and treated the animals with liraglutide at different doses. As a 
positive control, we also tested the effects of the classic selective serotonin re-uptake 
inhibitor (SSRI) fluoxetine to compare to the effects of liraglutide.  
 
 




Adult male C57BL/6N mice (8 weeks) were obtained from the animal center of Xiangya 
Medical School, Central South University. All animal treatments and experimental 
procedures were performed in accordance to National Institutes of Health (NIH) guideline 
(National Institutes of Health Publications, No. 80–23, revised 1978). The depression model 
was established by oral corticosterone (CORT) chronic administration. In brief, mice were 
treated with oral administration of CORT for 30 days (35 µg/ml/d, equivalent to 5 mg/kg/d) 
see (Siopi et al., 2016). To reach the goal in investigating the treatment effect of liraglutide, 
from the 15th day of the treatment with CORT, mice received intraperitoneal injection (IP) of 
different dosage of liraglutide (5, 20 nmol/kg) purchased from GL Biochem Ltd. Shanghai, 
China, or fluoxetine (FLX, 18 mg/kg/d; Sigma-Aldrich, US) or saline. The dosage of 
liraglutide was chosen, because it showed neuroprotective effects previously (Parthsarathy 




Tail suspension test 
The tail suspension test (TST) was conducted at 09:00am~10:00am. During the test, mice 
were suspended by the tip of their tails for 6 min. The distance from the nose of mice to the 
floor was 25cm. Mobility time (struggling exclude the movement of paws only) of mice were 
recorded for analyzing depressive mood (Can et al., 2012). The activity of mice was video 
recorded, and the mobility time was recorded by an observer blind to treatment.  
 
Forced swimming test 
The forced swimming test was conducted on the same day of TST at 17:00~18:00pm. Mice 
were put into a cylinder water tank (30 cm height × 20 cm diameters) with water temperature 
at 23~25°C for 6min. The mobility time within last 4 min (define the first 2 min as 
habituation) including struggling and free swim time were recorded for analyzing. The 
movements of mice was video recorded, and the mobility time was recorded by an observer 
blind to treatment. 
 
Open field test for anxiety  
Mice were put into an open field with the size of 43cm × 43cm for 10min. Mice could freely 
move in the arena. Duration of the animal traveled in the central area (20cm square region in 
center of the arena) was recorded to analyze the anxiety level. The Open field was cleaned 
with 75% ethanol before each test. The time of mice to spent in the central region was 
recorded by an observer blind to treatment. 
 
Elevated Plus Maze 
Elevated plus maze (EPM) was conducted on a plus-cross-shaped apparatus that was elevated 
58 cm above the floor and comprised two open and two closed arms (30Í6 cm) that 
extended	from a central platform (7Í7 cm). Mice were free to move on the maze for 10min. 
The time spent and entries in center, open arm, and closed arm zones were calculated (Siopi 
et al., 2016). The time of mice to spent in the both open arms and closed arms region were 
recorded by an observer blind to treatment. 
 
 
Hippocampal Slice Electrophysiology Recording  
 
Brains were quickly removed and submerged in ice-cold oxygenated sucrose-replaced 
artificial cerebrospinal fluid (ACSF) cutting solution containing (in mM) 206 sucrose, 2 KCl, 
2 MgSO4, 1.25 NaH2PO4, 1 CaCl2, 1 MgCl2, 26 NaHCO3, 10 d-glucose, pH 7.4, 315mOsm. 
Transverse slices (300 µm thickness) from the middle portion of each hippocampus were cut 
with the vibroslicer (VT1200 S, Leica, Germany). After dissection, slices were incubated in 
ACSF that contained the following (in mM): 124 NaCl, 2 KCl, 2 MgSO4, 1.25 NaH2PO4, 2.5 
CaCl2, 26 NaHCO3, 10 D-glucose (pH 7.4), 310 mOsm, in which they could recover for at 
least 90 min before recording. A single slice was then transferred to the recording chamber 
and submerged beneath continuously perfuse of ACSF that had been saturated with 95% O2 
and 5% CO2.  
A bipolar stimulating electrode (FHC Inc., Bowdoin, ME) was placed in the Schaffer 
collaterals to deliver test and conditioning stimuli. A borosilicate glass recording electrode 
filled with ACSF was positioned in stratum radiatum of CA1, 200~300 µm from the 
stimulating electrode. fEPSP in the CA1 region were induced with an intensity that elicited a 
fEPSP amplitude 40%–50% of maximum. Test responses were recorded for 30–60 min prior 
to beginning the experiment to assure stability of the response. Once a stable test response 
was attained, experimental treatments were added to the 10 ml ACSF perfusate, and a 
baseline was recorded for an additional 30 min. To induce LTP, high frequency stimulation 
(HFS) including two consecutive trains (1s) of stimuli at 100 Hz separated by 20 s were 
applied to the slices, a protocol that induced LTP lasting approximately 1h. The field 
potentials were amplified 100× using an Axon Instruments 200B amplifier and digitized with 
Digidata 1322A. Data were sampled at 10 kHz and filtered at 2 kHz. Traces were obtained by 
pClamp 9.2 and analyzed using the Clampfit 9.2 program. LTP values reported throughout 




After LTP recording, the hippocampal slices were immediately fixed with 4% 
paraformaldehyde (PFA) for 24 h. Then, the slices were dehydrated in 30% of sucrose 
solution for 2 days, and embedded with frozen embedding medium OCT (Leica Inc., 
Germany). Corona-brain sections (thickness 40 µm) were prepared with freezing microtome 
(Leica Inc., Germany). Before IHC, antigen was retrieved with pH6.0 citrate acid buffer 
heated in micro-oven for 10 min (high power). Then sections were washed with PBS (0.4% 
TritonX-100) for 3 times (15 min per time) and blocked with 5% goat serum (Zhongshan 
Jinqiao Inc., China) for 30 min. Primary doublecortin (DCX) antibody (Rabbit-anti-DCX, 
CELL SIGNALING TECHNOLOGY, 1:500) was incubated with the brain section overnight 
at 4°C. Secondary fluorescent antibodies (Goat-anti-Rabbit-Alexa 488, Thermo Fisher, 
1:800) was incubated in room temperature for 2 h after washing the primary antibodies with 
PBS for 3 times (5 min per time). Finally, sections were incubated with DAPI (4',6-
diamidino-2-phenylindole) solution for 10 min. DCX+ NPCs in hippocampal DG were 
observed with the confocal microscope (Zeiss, LSM 700, German). Cell density were 




Plasma preparation was performed at 09:00am-10:00am. For baseline corticosterone 
detection, mice were normally raised before blood collection. Blood was collected from the 
tail vein before stress treatment. Then, mice underwent the acute stress treatment by 
restraining mice into a plastic tube with 11 air holes for 30min. Afterward, blood was 
collected again. Plasma was immediately prepared by centrifugation of the blood at 4000rpm 
(1800g) at 4°C for 15min. ACTH ELISA kit (Enzo Life Science, US) was employed for 
plasma tests of ACTH levels. Samples were all diluted 40 times following the instruction of 
ELISA kit beforehand. A plate reader (Bio-rad 680, US) was used for detecting the OD value 




Hippocampal slices were collected and protein lysate was prepared with RIPA lysis buffer 
with 1% of phosphatase inhibitor (Beyotime Inc., China). The BCA method was applied to 
quantitate the protein concentration of each sample. 40µg of the protein was loaded in each 
well of the gel (10% SDS-PAGE separation gel). SDS-PAGE electrophoresis was performed 
to separate the proteins by the molecular size. Transfer of proteins onto 0.45µm PVDF 
membrane was done using the semi-dry transfer method. The membrane was blocked with 
0.1% BSA for 1h at room temperature. Primary antibodies (Rabbit anti-DCX, 1:1000; Rabbit 
anti-phosph-GR (S211), 1:1000; Rabbit anti-GR, 1:1000; Rabbit anti-β-catenin, 1:1000; 
Rabbit anti-phosph-GSK3-β (S9); Rabbit anti- GSK3-β; and Rabbit anti-GAPDH, 1:2000; 
Cell Signaling Technology, US) were incubated with the membrane at 4℃ overnight. The 
membrane was washed with TBST buffer for 3 times (15min each time). The secondary 
antibody (Goat anti-rabbit HRP, CELL SIGNALING TECHNOLOGY, 1:5000) was 
incubated with the membrane for 1h at room temperature. Protein bands were visualized with 
enhanced chemiluminescent (ECL, Pierce, Rockford, IL, USA) and analyzed by the imaging 




All results were presented as mean ± standard error and displayed with the graphic software 
Prism 6 (GraphPad, GraphPad Software Inc., La Jolla, CA, USA). The software SPSS 16.0 
(GraphPad) was used for statistical analysis. A two-way ANOVA was used for analyzing data 
related to time changes (LTP recording). The rest of analysis was conducted by one-way 
ANOVA. Statistically significance was classed as p<0.05. Mark the significance comparing 
through *: p<0.05, **: p<0.01; ***: p<0.001 compared with control; #: p<0.05, ##: p<0.01; 




Liraglutide attenuates the depressive-/anxiety-like behaviors induced by CORT 
 
We conducted the behavioral tests to assess whether liraglutide could ameliorate the 
depression- associated symptoms induced by CORT administration. After 30 days of CORT 
administration and 15 days liraglutide/fluoxetine treatment, the tail suspension test (TST) and 
forced swim test (FST) were performed to evaluate any depressive behavior (Fig 1 A, n=12 
per group). CORT administration resulted in decreased mobility in the TST and FST (Fig 1 B, 
C; one-way ANOVA, p<0.001), which indicates that depression had been induced by chronic 
stress. No significant effects were observed with the lower dosage of liraglutide to the 
depressive behavior (Fig 1 B, C; one-way ANOVA, p=0.543 in TST; p=0.784 in FST), but 
the high dosage of liraglutide (20nmol/kg/d) improved the mobility time in TST and FST, 
indicating the antidepressant effects of liraglutide (Fig 1 B, C; one-way ANOVA, p<0.001 in 
TST; p<0.01 in FST). As the positive control, antidepressant fluoxetine (FLX) also attenuated 
the depression- like behaviors of the mice in the TST and FST (Fig 1 B, C; one-way ANOVA, 
p<0.001 in TST; p=0.0011 in FST). Elevated plus maze (EPS) as well as open field test were 
then performed to assess the anxiety- like behavior of the mice and the effects of liraglutide 
as an anxiolytic. During EPS, CORT administration caused a shortening of exploration time 
in the open arm (Fig 1 D, one-way ANOVA, p<0.001). Additionally, CORT administration 
also decreased the tendency of mice to explore the central region of open field (Fig 1 E, one-
way ANOVA, p<0.001). Those results document the anxiety-like behavior induced by 
chronic CORT administration. Unlike the positive control FLX (Fig 1 D, one-way ANOVA, 
p<0.001), both low and high dosage of liraglutide did not increase the time of the mice spent 
in open arm (Fig 1 D, one-way ANOVA, p=0.1413 for low dosage; p=0.1499 for high 
dosage). However, both dosages of liraglutide prolonged the exploration time in central area 
of open field (Fig 1 E, one-way ANOVA, p=0.0485 for low dosage; p=0.029 for high 
dosage), which resemble the effects of FLX (Fig 1 E, one-way ANOVA, p=0.0342). Taken 
together, liraglutide treatment could attenuate most depressive- and anxiety- like behaviors 
induced by chronic stress. 
 
Liraglutide reduces the secretion of the stress hormone ACTH under stress stimulation 
 
To investigate the effects of liraglutide on the stress response of the depression model, we 
tested the levels of the stress hormone adrenocorticotropic hormone (ACTH) (n=6 per group, 
Fig 2 A). The level of ACTH in plasma were tested before and after stress treatment to test 
the changes of the response to stress. The result demonstrates that CORT group mice showed 
a significantly increased production of ACTH under stress (Fig 2 A, B, two-way ANOVA, 
p<0.0001 compared with control). Compared with the CORT group, liraglutide at both 
dosages ameliorated the level of the stress response by down- regulating the ACTH levels 
when mice underwent the restraint stress treatment (Fig 2 B, two-way ANOVA, p<0.0001 
compare with CORT group). In addition, the positive control FLX also showed the same 
effects (Fig 2, A, B, two-way ANOVA, p<0.0001 compare with CORT group). 
 
Liraglutide treatment enhanced synaptic plasticity in hippocampal area CA1 
 
LTP levels were analyzed in 5 groups (n=6 per group, Fig 3 A). We confirmed that CORT 
administration resulted in decreased LTP induction and maintenance compared with control 
(Fig 3 B, two-way ANOVA, p<0.001), which was reflected by decreased fEPSPs at different 
time points after high-frequency stimulation (HFS) (Fig 3 C, two-way ANOVA; p<0.001 at 
0min; p=0.0014 at 30min; p=0.003 at 60min). Low dosage of liraglutide treatment did not 
have an effect compared with CORT group (Fig 3 B two-way ANOVA, p=0.6015), but high 
dosage liraglutide significantly improved the strength of LTP that had been impaired by 
CORT administration (Fig 2 B two-way ANOVA, p<0.001). Compared with the CORT 
group, high dosage of liraglutide treatment increased fEPSPs as measured at 3 time points 
after HFS (Fig 3 C, two-way ANOVA; p<0.001 at 0min; p=0.0377 at 30min; p=0.0069 at 
60min). Interestingly, FLX treatment did not show an increase in fEPSPs at 0min (Fig 3 C, 
two-way ANOVA; p=0.0092 at 0min; p=0.9955 at 30min; p=0.9596 at 60min). Although a 
two-way ANOVA test showed a significant improvement of LTP by FLX in area CA1 (Fig 3 
B, two-way ANOVA, p<0.001), the effects of FLX on LTP maintenance was inferior 
compared to liraglutide. Taken together, liraglutide attenuates the chronic stress induced 
synaptic impairment, which may contribute to its protective effect in depression. 
 
Liraglutide promotes adult neurogenesis in the dentate gyrus area of the hippocampus 
 
We analyzed the expression level of hippocampal doublecortin (DCX), which acts as the 
marker of the immature developing neurons (n=6 per group, Fig 4). The results indicate that 
chronic treatment of CORT resulted in decreased levels of DCX in the hippocampus (Fig 4 A, 
B, one-way ANOVA, CORT vs Control: p<0.0001). Compared with the CORT group, 
20nm/kg liraglutide treatment showed increased levels of DCX in the hippocampus (Fig 4 A, 
B, one-way ANOVA, CORT vs 20nm/kg: p=0.149). This effect was also observed in the 
positive control FLX treatment group (Fig 4 A, B, one-way ANOVA, CORT vs FLX: 
p=0.0067). CORT treatment caused a decreased density of DCX+ neurons in DG (Fig 4 C, D, 
one-way ANOVA, CORT vs Control: p<0.0001). Liraglutide treatment at the high dosage 
(20nm/kg) significantly increased the density of DCX+ immature neurons in comparison 
with CORT (Fig 4 C, D, one-way ANOVA, CORT vs 20nm/kg: p=0.0457). This effect was 
also found in the positive control FLX treated group (Fig 4 C, D, one-way ANOVA, CORT vs 
FLX: p=0.0307). Taken together, the results suggest that liraglutide can enhance adult 
hippocampal neurogenesis, which is impaired in depression. 
 
Liraglutide reduces the over-activation of GSK3β in depression  
 
We tested the expression level of GSK3β as well as its phosphorylation at the Ser9 site (Fig 5 
A). The results show that there was no significant change of the total expression level of 
GSK3β in the hippocampus among different groups (Fig 5 A, B, n=6, one-way ANOVA, 
p=0.3904). When comparing the phosphorylation level of GSK3β at Ser9 site, the CORT 
group presented a down- regulation compared to control (Fig 5 A, C, n=6, one-way ANOVA, 
CORT vs Control: p<0.0001). In addition, treatment of liraglutide at the high dosage 
(20nm/kg) increased the phosphorylation level of GSK3β at Ser9 in comparison with the 
CORT group (Fig 5 A, C, n=6, one-way ANOVA, 20nm/kg vs CORT: p=0.0312). The lower 
dosage of liraglutide (5nm/kg) did not reach statistical significance (Fig 5 A, C, n=6, one-way 
ANOVA, 5nm/kg vs CORT: p=0.2378). Moreover, the positive control FLX did not 
significantly reduce the activity of GSK3β by increasing the phosphorylation level at Ser9 




Our study showed that the GLP-1 drug liraglutide has beneficial effects on CORT induced 
depressive- and anxiety- like symptoms. In addition to the observed protective effects in 
neurodegenerative diseases, liraglutide may act as an antidepressant drug. The behavioral 
studies indicate that liraglutide treatment attenuates the chronic CORT induced depressive-
/anxiety- behaviors. The performance of the mice treated with the higher dose of liraglutide is 
as good as the FLX treated animals. Therefore, the antidepressant effects shown here is 
promising and deserves further research. Liraglutide also normalized the ACTH levels after 
stress treatment, attenuating depressive-/anxiety- like behaviors and regulating the stress 
endocrine system. 
LTP of synaptic activity in the hippocampus and adult neurogenesis have been implied to 
play a key role in memory formation and hippocampal-dependent behaviors (Hawkins et al., 
1998; Stuchlik, 2014). Impaired hippocampal functions, especially decreased neural plasticity 
and LTP, contributes to the development of depression (Borsini and Zunszain, 2016; Dina et 
al., 2017). In current study, we found that liraglutide treatment normalized LTP in the 
hippocampus after CORT treatment, and promoted adult neurogenesis in hippocampus that 
had been impaired by CORT (Fig 3~4). This result suggests that the improvement of LTP as 
well as neurogenesis are correlated with the antidepressant effects of liraglutide. These results 
confirm previous research in AD animal models that showed improved  neurogenesis in the 
dentate gyrus as well as LTP induction after liraglutide treatment (Hamilton et al., 2011; 
McClean et al., 2011a). Collectively, the anti-depressant activity of liraglutide may be driven 
by regulating the neural plasticity in the adult hippocampus.  
GSK3β signaling is involved in the regulation of glucose metabolism (Summers et al., 1999). 
Since metabolism disorders are one of the important risk factors to neurological diseases, 
metabolic factors could also play fundamental roles in the development of neurological or 
psychiatric diseases. Over-activity of GSK3β is also seen to play a role in depression-induced 
neural dysfunctions (Costemale-Lacoste et al., 2016), and GSK3β is a target for the effects of 
anti-depression treatments (Zunszain et al., 2013). Previous studies showed that the natural 
compound geniposide, a GLP-1 receptor agonist, could reverse the over-activation of GSK3β 
in a rat model of sporadic Alzheimer’s disease (Gao et al., 2014). However, whether 
liraglutide could attenuate over-activated GSK3β in a depression model had never been 
shown before. Here we demonstrate for the first time that liraglutide can attenuate the activity 
of GSK3β which was elevated by CORT treatment. This result indicates that regulating 
GSK3β activity plays a role in the neuroprotective effects of liraglutide in various 
neurological and psychiatric pathophysiologies.  
When comparing the effects of liraglutide with those of the standard antidepressant drug 
FLX, we found that both drugs show similar improvements in key biomarkers that were 
measured in our study. However, in the LTP study of synaptic activity in the hippocampus, 
FLX showed no improvement, while liraglutide clearly did. This indicates that the mode of 
action is different for both drugs on some extent. Moreover, based on the different target that 
liraglutide does not improve the neural functions by direct elevating certain kinds of 
neurotransmitters as traditional antidepressant like fluoxetine, it could be more suitable to get 
rid of other symptom induced by depression including insomnia, anorexia or even avoid the 
side effects induced by fluoxetine like obesity and addiction. Besides liraglutide, other GLP-1 
medications like DPP4 inhibitors, which have shown to perform therapeutic effects in 
Alzheimer’s disease models, might also have the potential as an antidepressant (D'Amico et 
al., 2010; Gault et al., 2015). Thus, the different mechanism between anti-diabetic drugs and 
fluoxetine is worthy of further research.  
Some limitation cannot be avoided in this study. For example, the model we employed here 
cannot mimic the unpredictable stress- induced type of depression. But based on the theory of 
HAP axis hyperactivation, it is a good model to use for developing antidepressants. On the 
other hand, a treatment of liraglutide on control mice should be added for assess the side 
effects of the drug. However, based on previous reports, chronic treatment of liraglutide did 
not affect the cognitive functions in wild type mice, so we did not include a drug treated 
control group in our study (McClean et al., 2011b).   
Taken together, the anti-diabetic drug liraglutide has the potential to act as a therapeutic 
treatment of depression. The underlying mechanisms include promoting hippocampal LTP 
and adult neurogenesis in a GSK3β dependent mechanism. The drug is widely used and is 
safe to take for people who do not have diabetes. Currently, a clinical trial is ongoing that 
tests the effects of liraglutide in non-diabetic Alzheimer’s patients (Hölscher, 2016). Further 
research is needed to compare GLP-1 mimetics with currently available treatments fo 
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Figure 1: Liraglutide showed protective effects in the corticosterone (CORT) induced depression 
model in behavioral tasks  
(A) Experimental procedure of the study. CORT was administrated via drinking water to induce 
depression- like behavior in a 30-days period. Liraglutide with different dosages were started to treat 
the depression model from the 15th day to the end. (B) Forced swim test (FST). In FST, the CORT group 
showed decreased mobility time in comparison with control (one-way ANOVA, ***: p<0.001). 
Compared with the CORT group, liraglutide at the higher dosage (20nm/kg) increased the mobility time 
(one-way ANOVA, ###: p<0.001). The positive control fluoxetine (FLX) also showed the same effects 
in FST (one-way ANOVA, ###: p<0.001 in compare with CORT). (C) Tail suspension test (TST). In 
the TST, the CORT group showed significant decreased mobility time in comparing with control (one-
way ANOVA, ***: p<0.001). Compared with CORT group, liraglutide at the higher dosage (20nm/kg) 
increased the mobility time (one-way ANOVA, #: p<0.05). FLX showed similar effects (one-way 
ANOVA, ##: p<0.01 in compare with CORT). (D) Elevated plus maze (EPS) test. Compared with 
control, CORT treatment decreased the time in the open arm (one-way ANOVA, ***: p<0.001). FLX 
treatment increased the exploration in the open arm (one-way ANOVA, ###: p<0.01 compared with 
CORT). (E) Open field test (OFT). Compared with control, CORT decreased exploration time in the 
central region of the open field (one-way ANOVA, ***: p<0.001). Both low and higher doses of 
liraglutide increased the exploration time (one-way ANOVA, #: p<0.05 ##: p<0.01 compared with 
CORT). FLX treatment showed similar effects (one-way ANOVA, #: p<0.05 in compare with CORT). 
(n=12 per group) 
  
  
Figure 2: Enhanced ACTH levels in the blood are reduced by liraglutide treatment 
(A) Experimental protocol to test the adreno-cortico-tropic-hormone (ACTH) of adult mice. Mice in 
different groups were collected with blood at normal condition. Then after underwent the 30min 
restraint stress, the blood was collected again to prepare the plasma sample. (B) Statistical analysis 
indicates that no different level of ACTH showed among different groups under normal condition. 
Although restraint induced the increasing ACTH in plasma, CORT administrated group presented the 
higher ACTH level at stress condition compared with control (two-way ANOVA, F (4, 50) = 9.593, p 
< 0.0001; CORT vs control under stress ***: p<0.001). In addition, different dosages of liraglutide 
reduced the CORT induced hyper-elevation of ACTH under stress, which had same effect with 
fluoxetine (two-way ANOVA, under stress, compare with CORT group ###: p<0.001). N=6 per group. 
 
Figure 3: Liraglutide prevented the CORT induced impairment of hippocampal LTP   
(A) Representative fEPSP traces recorded prior and after HFS. (B) fEPSP slopes before HFS and after 
HFS for each group. (C) Statistical analysis to compare the fEPSP slope values of different groups at 
different time point after HFS. CORT administration decreased fEPSPs at all three time points (0, 30min 
and 60min) (two-way ANOVA, ***: p<0.001 in compared with control). The high dosage of liraglutide 
(20nm/kg) reversed this effects. In compared with CORT, the high dose of liraglutide increased the 
slopes of fEPSP at three time points (two-way ANOVA, ###: p<0.001, ##: p<0.01, #: p<0.05 compared 
with CORT). However, treatment with FLX did not show any effects. N=6 per group. 
 
Figure 4: Liraglutide promotes adult neurogenesis in the hippocampus 
 (A) Western blot bands to show the levels of doublecortin (DCX). (B) DCX levels in the 5 groups. 
CORT induced a decrease of DCX in the hippocampus (one-way ANOVA, ***: p<0.001 compared with 
control). The high dosages of liraglutide treatment elevated the DCX levels (one-way ANOVA, #: 
p<0.05 compared with CORT). FLX treatment enhanced DCX levels (one-way ANOVA, ##: p<0.01 
compared with CORT). (C) Immunofluorescence sample image of DCX+ immature neurons in the DG 
(bar=50µm). (D) Cell density of DCX+ immature neurons in the DG region. CORT treatment 
significantly reduced the density of immature neurons (one-way ANOVA, ***: p<0.001 compared with 
control). The high dose of liraglutide increased the immature neuron density (one-way ANOVA, #: 
p<0.05 compare with CORT). FLX increased the levels of DCX+ neurons (one-way ANOVA, #: p<0.05 
compared with CORT). (n=6 per group). 
 
Figure 5: Liraglutide inhibits the activity of GSK3β by regulating the phosphorylation level 
 (A) Western blot bands to show the phosphorylation of GSK3β at Ser9 and the total GSK3β levels (B) 
Levels of GSK3β total protein. One-way ANOVA showed there is no difference among all groups in 
the total protein levels. (C) Phosphorylation level of GSK3β at Ser9. CORT administration resulted in 
a decreased phosphorylation of GSK3β at Ser9 (one-way ANOVA, ***: p<0.001, compared with 
control). In compared with CORT, treatment of liraglutide with high dosage increased GSK3β 
phosphorylation at Ser9 (one-way ANOVA, #: p<0.05). In the FLX group, there was no increase of 
GSK3β phosphorylation at Ser9. (n=6) per group. 
	
	
